News

Inside AI Assisted Software Development and why tools are not enough (Part 1)
Using AI, architects can quickly draw up diagrams to easily visualise these relationships and standardise dependency versions ...
powerelectronicsnews26d
Powering the Future: How NVIDIA and Infineon Are Reinventing AI Data Center Architecture
The block diagram of Figure 2 ... more detail what the 800V DC platform data center looks like. Figure 2: Future GW-scale data center architecture (Source: Infineon) Here, the AC mains (typically ...
InfoWorld11d
Building an analytics architecture for unstructured data and multimodal AI
AI and multimodal data are reshaping analytics. Success requires architectural flexibility: matching tools to tasks in a ...
Data Center Frontier1h
Executive Roundtable: Standardization vs. Flexibility in Data Center Designs for the AI Era
As AI reshapes infrastructure demands, data center leaders are rethinking the balance between standard designs and custom ...
How AI-driven data architectures are reinventing cybersecurity and public safety
In a world where digital transformation is accelerating at an unprecedented pace, AI-driven data analytics has become the cornerstone of both cybersecurity and public safety innovation. As ...
InfoQ4d
Decentralized Architecture Needs More Than Autonomy
Architectural success in decentralized systems depends more on how decisions are made than on system design alone. Replacing ...
Yahoo Finance25d
Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
SAN DIEGO, May 28, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of data from the Phase 2 study of NBI-1117568 in adults with schizophrenia ...
Yahoo Finance23d
Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing
TARRYTOWN, N.Y., May 31, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced detailed analyses from the Phase 3 C ... include additional data for the primary ...